Chwilio eraill:
revolves. » resolves. (Ehangu'r Chwiliad), evolved. (Ehangu'r Chwiliad), evolve. (Ehangu'r Chwiliad), revolved. (Ehangu'r Chwiliad), revolve. (Ehangu'r Chwiliad)
revolvesdsds. » resolvesdsds. (Ehangu'r Chwiliad), evolveddsds. (Ehangu'r Chwiliad), evolvedsds. (Ehangu'r Chwiliad), revolveddsds. (Ehangu'r Chwiliad), revolvedsds. (Ehangu'r Chwiliad)
evolves. » evolved. (Ehangu'r Chwiliad), evolve. (Ehangu'r Chwiliad)
revolves. » resolves. (Ehangu'r Chwiliad), evolved. (Ehangu'r Chwiliad), evolve. (Ehangu'r Chwiliad), revolved. (Ehangu'r Chwiliad), revolve. (Ehangu'r Chwiliad)
revolvesdsds. » resolvesdsds. (Ehangu'r Chwiliad), evolveddsds. (Ehangu'r Chwiliad), evolvedsds. (Ehangu'r Chwiliad), revolveddsds. (Ehangu'r Chwiliad), revolvedsds. (Ehangu'r Chwiliad)
evolves. » evolved. (Ehangu'r Chwiliad), evolve. (Ehangu'r Chwiliad)
-
221
Droplets as Cell Models: Chemical Gradient-Induced Directional Filopodia Formation
Cyhoeddwyd 2025Pynciau: -
222
Droplets as Cell Models: Chemical Gradient-Induced Directional Filopodia Formation
Cyhoeddwyd 2025Pynciau: -
223
-
224
-
225
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in μM range.
Cyhoeddwyd 2025Pynciau: -
226
-
227
-
228
-
229
-
230
-
231
The null catalytic main model 3.1 with <i>K</i><sub><i>M</i></sub> values in μM range.
Cyhoeddwyd 2025Pynciau: -
232
-
233
-
234
-
235
-
236
-
237
The null catalytic main model 3.2 and <i>K</i><sub><i>M</i></sub> values in 0.1 μM range.
Cyhoeddwyd 2025Pynciau: -
238
-
239
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in 0.1 μM range.
Cyhoeddwyd 2025Pynciau: -
240
Trialblazers: “Build-a-Trial” workshops for people with psoriatic arthritis
Cyhoeddwyd 2024“...This was to be followed in June 2024 by an application to the Medical Research Council (MRC) funding stream for a grant in understanding public involvement in non-clinical research.</p><p dir="ltr">In collaboration with the NDORMS’ public-involvement group, Open Arms, and led by clinician researcher Laura Coates, the team developed and ran Build-a-Trial workshops with patients to design this much needed trial from scratch. ...”